Cerenome is trading at $1.66, down 6.65%, with no clear October 2 company-specific catalyst identified. - On October 1, Lake Street lowered its price target from $50 to $31 and maintained a Buy rating. Its report cited updated model assumptions and financing dilution, but does not establish a link to the current decline. - Broader equities were higher after weaker jobs data eased rate concerns, so Cerenome’s decline did not track the overall market direction.